文献速递系统性红斑狼疮

不同治疗方案对系统性红斑狼疮患者SARS-CoV-2疫苗抗体应答的影响

Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-03-04

该前瞻性对照研究纳入232例未感染SARS-CoV-2的SLE患者和58例对照,均接种2剂Sinovac-CoronaVac(间隔28天)。第69天SLE患者血清转化率70.2%低于对照98.1%(P<0.001),中和抗体阳性率61.5%低于对照84.6%(P=0.002);泼尼松和吗替麦考酚酯与较低血清转化独立相关,羟氯喹可能提高血清转化,未观察到中重度不良事件。

要点

  • SLE患者接种Sinovac-CoronaVac后第69天血清转化率70.2%、中和抗体阳性率61.5%,均低于对照。
  • 泼尼松(OR 0.215)和吗替麦考酚酯(OR 0.201)与较低血清转化相关,羟氯喹使血清转化增加2.5倍。
  • 羟氯喹单药治疗者血清转化率与对照相似(100% vs 98.1%,P=1.000),未观察到中重度不良事件。

核心结论

  • Sinovac-CoronaVac在未感染SARS-CoV-2的SLE患者中具有中等免疫原性和极好的安全性。
  • 羟氯喹可能提高血清转化,而泼尼松和吗替麦考酚酯对疫苗应答有重大不利影响。
  • 作者认为需研究暂时停用吗替麦考酚酯或接种疫苗加强针的作用。

研究设计与样本

  • 前瞻性对照研究,纳入232例未感染SARS-CoV-2的SLE患者和58例未感染对照,均接种2剂Sinovac-CoronaVac,间隔28天(第0天/第28天)。
  • 在第0天、第28天和第69天分析抗SARS-CoV-2 S1/S2 IgG血清转化和中和抗体阳性率,并评估单个药物对免疫应答和安全性的影响。

主要发现

  • 第69天SLE患者血清转化率为70.2%,对照组为98.1%(P<0.001);SLE患者中和抗体阳性率为61.5%,对照组为84.6%(P=0.002)。
  • 第69天单因素分析中,泼尼松使用与较低血清转化相关(OR 0.215 [95%CI 0.108-0.427],P<0.001),吗替麦考酚酯使用与较低血清转化相关(OR 0.201 [95%CI 0.107-0.378],P<0.001),羟氯喹使用使血清转化增加2.5倍(P=0.011)。
  • 接受羟氯喹单药治疗的SLE患者第69天血清转化率与对照组相似(100% vs 98.1%,P=1.000)。
  • 多因素分析中,泼尼松和吗替麦考酚酯使用与较低血清转化(P<0.001)和较低中和抗体阳性率(P<0.001)独立相关。
  • 安全性分析未观察到中重度不良事件。

关键数值与推荐

  • SLE患者第69天血清转化率70.2% vs 对照组98.1%(P<0.001)。
  • SLE患者第69天中和抗体阳性率61.5% vs 对照组84.6%(P=0.002)。
  • 泼尼松使用与较低血清转化相关:OR 0.215(95%CI 0.108-0.427),P<0.001。
  • 吗替麦考酚酯使用与较低血清转化相关:OR 0.201(95%CI 0.107-0.378),P<0.001。
  • 羟氯喹使用使血清转化增加2.5倍(P=0.011);羟氯喹单药治疗者血清转化率100% vs 对照98.1%(P=1.000)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To date, the only study that has assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but the sample size precluded an accurate analysis of the effect of individual drugs. Therefore, we evaluated the immunogenicity of an inactivated SARS-CoV-2 vaccine (Sinovac-CoronaVac) and the influence of different medications in SLE. Safety was also assessed. METHODS: We conducted a prospective controlled study of 232 SARS-CoV-2-naive SLE patients and 58 SARS-CoV-2-naive controls who were vaccinated with 2 doses of Sinovac-CoronaVac with a 28-day interval (day 0/day 28 [D0/D28]). Immunogenicity analysis at D0/D28 and D69 included anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC) and neutralizing antibodies (NAb) positivity. The influence of individual drugs on immune response and safety was assessed. RESULTS: Patients and controls were well balanced for age (P = 0.771). At D69, SLE patients showed a moderate SC (70.2% versus 98.1%; P < 0.001) and moderate frequency of NAb positivity (61.5% versus 84.6%; P = 0.002), although both frequencies were lower than in controls. Factors associated with lower SC in univariate analysis at D69 were prednisone use (odds ratio [OR] 0.215 [95% confidence interval (95% CI) 0.108-0.427], P < 0.001) and mycophenolate mofetil (MMF) use (OR 0.201 [95% CI 0.107-0.378], P < 0.001), whereas hydroxychloroquine (HCQ) use led to a 2.5 increase in SC (P = 0.011). SLE patients who were receiving HCQ monotherapy had similar SC to controls at D69 (100% versus 98.1%; P = 1.000). In multivariate analysis, prednisone and MMF use were independently associated with lower SC (P < 0.001) and NAb positivity (P < 0.001). Safety analysis revealed no moderate/severe adverse events. CONCLUSION: Sinovac-CoronaVac has a moderate immunogenicity in SARS-CoV-2-naive SLE patients with an excellent safety profile. We further demonstrate that HCQ may improve SC, whereas prednisone and MMF had a major deleterious effect in vaccine response, reinforcing the need to investigate the role of temporary MMF withdrawal or a vaccine-booster dose (ClinicalTrials.gov identifier: NCT04754698).

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Yuki EFN, Borba EF, Pasoto SG, et al. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022. PMID: 34806342. doi:10.1002/acr.24824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。